» Articles » PMID: 23986389

Design and Synthesis of the Stabilized Analogs of Belactosin A with the Unnatural Cis-cyclopropane Structure

Overview
Journal Org Biomol Chem
Specialties Biochemistry
Chemistry
Date 2013 Aug 30
PMID 23986389
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The belactosin A analog 2a, having the unnatural cis-cyclopropane structure instead of the trans-cyclopropane structure in belactosin A, is a much more potent proteasome inhibitor than belactosin A. However, its cell growth inhibitory effect is rather lower than that expected from its remarkable proteasome inhibitory effect, probably due to its instability under cellular conditions. We hypothesized that the instability of 2a was due to chemical and enzymatic hydrolysis of the strained β-lactone moiety. Thus, to increase the stability of 2a by chemical modification, its analogs with a sterically more hindered β-lactone moiety and/or cyclopropylic strain-based conformational restriction were designed and synthesized, resulting in the identification of a stabilized analog 6a as a proteasome inhibitor with cell growth inhibitory effects. Our findings suggest that the chemical and biological stability of 2a is significantly affected by the steric hindrance around its β-lactone carbonyl moiety and the conformational flexibility of the molecule.

Citing Articles

Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D.

Zheng Q, Zhang Z, Guiley K, Shokat K Nat Chem Biol. 2024; 20(9):1114-1122.

PMID: 38443470 PMC: 11357986. DOI: 10.1038/s41589-024-01565-w.


Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents.

Viera C, Stevens B, Viera T, Zielinski C, Uranga L, Rogelj S R Soc Open Sci. 2022; 9(9):220358.

PMID: 36177203 PMC: 9515629. DOI: 10.1098/rsos.220358.


Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.

Hubbell G, Tepe J RSC Chem Biol. 2021; 1(5):305-332.

PMID: 33791679 PMC: 8009326. DOI: 10.1039/d0cb00111b.


A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.

Zhu M, Harshbarger W, Robles O, Krysiak J, Hull K, Cho S Bioorg Med Chem. 2017; 25(11):2901-2916.

PMID: 28236510 PMC: 5522751. DOI: 10.1016/j.bmc.2017.01.020.